United Therapeutics CorporationUsage: Orenitram treats pulmonary arterial hypertension (PAH) in adults (WHO Group 1) to delay disease progression and improve exercise capacity. Most studied in WHO functional class II-III patients with idiopathic, heritable, or connective tissue disease-associated PAH.